Skip to main content

Clinical Trials Using Fludarabine Phosphate

Review the clinical trials studying fludarabine phosphate on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 26-47 of 47

Modified Immune Cells (Autologous iC9.GD2.CAR.IL-15 T cells) for Treating Patients with Relapsed or Refractory High Risk Neuroblastoma, Ganglioneuroblastoma, or Osteosarcoma
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
T Lymphocytes Expressing the Kappa Chimeric Antigen Receptor (CAR) and CD28 Endodomain for the Treatment of Relapsed or Refractory B cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Donor Blood Stem Cells (Ex Vivo TCR Alpha/Beta and CD19-Depleted Stem Cells) for the Prevention of Graft-versus-Host Disease in Pediatric Patients with Blood Cancer
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Nivolumab in Combination with Lymphodepletion Chemotherapy, CD40L-Augmented Tumor Infiltrating Lymphocytes, and Interleukin-2 for the Treatment of Recurrent/Refractory Stage IV Non-small Cell Lung Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Genetically Engineered Cells (LMY-920) for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Autologous IC9-CAR19 T cells in Treating Patients with Recurrent or Refractory Acute Lymphoblastic Leukemia
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Human Papillomavirus (HPV)-Specific Donor T-Cell Infusion for the Treatment of Advanced HPV16-Associated Head and Neck Squamous Cell Cancer
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
211At-OKT10-B10 and Fludarabine Alone or in Combination with Cyclophosphamide and Low-Dose TBI before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
Status: Approved
Location: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Cell Therapy (CIML NK Cells) for the Treatment of Recurrent Myeloid Disease after Donor Blood Stem Cell Transplant
Status: Temporarily Closed to Accrual
Location: 3 locations
Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate before Donor Stem Cell Transplant in Treating Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients with Chronic Lymphocytic Leukemia
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
Tumor Infiltrating Lymphocytes and High-Dose Aldesleukin with or without Autologous Dendritic Cells in Treating Patients with Metastatic Melanoma
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas
A Study of Revumenib in Combination with Chemotherapy for Patients Diagnosed with Relapsed or Refractory Leukemia
Status: Temporarily Closed to Accrual
Location: 75 locations
Venetoclax in Combination with Conventional Chemotherapy for the Treatment of Pediatric Patients with Acute Myeloid Leukemia
Status: Temporarily Closed to Accrual
Location: 9 locations
Testing the Safety and Feasibility of HER2 CAR T Cells in Patients with Recurrent or Refractory Ependymoma
Status: Temporarily Closed to Accrual
Location: 10 locations
Fludarabine and Cyclophosphamide with or without Rituximab before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Temporarily Closed to Accrual
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
Venetoclax, Busulfan, Fludarabine, Azacitidine, Decitabine, and Cedazuridine in Treating Patients with High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndromes Undergoing Donor Stem Cell Transplantation
Status: Temporarily Closed to Accrual
Location: 2 locations
Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients with Relapsed Hematologic Cancers Undergoing a Second or above Donor Stem Cell Transplant
Status: Temporarily Closed to Accrual
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
Universal Donor Natural Killer Cells in Combination with Aldesleukin and Vactosertib for the Treatment of Patients with Locally Advanced or Metastatic Colorectal, Gastric and Esophageal Cancers and Relapsed or Refractory Hematologic Cancers
Status: Temporarily Closed to Accrual
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults with Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial
Status: Temporarily Closed to Accrual
Location: 6 locations